Publications by authors named "Eva Romero-Gonzalez"
Article Synopsis
- The study investigates how clinical factors and the HLA-DQA1*05 genetic marker affect the discontinuation of biologic treatments in patients with inflammatory bowel disease (IBD).
- A total of 150 IBD patients were analyzed, revealing that nearly half (47%) discontinued treatment, with primary non-response (PNR) more common in those with Ulcerative Colitis (UC) and secondary loss of response (SLR) linked to flare-ups and specific drugs like infliximab.
- The findings emphasize the significance of both HLA genetics and clinical factors, especially in patients using adalimumab without immunosuppressants, highlighting the complexity of treatment responses in IBD.*